AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia, was announced by NeoGenomics Inc.
As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP).
